Latest Insider Transactions at Apyx Medical Corp (APYX)
This section provides a real-time view of insider transactions for Apyx Medical Corp (APYX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apyx Medical Corp to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apyx Medical Corp's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 13
2024
|
Matthew C Hill Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,336
+40.51%
|
$5,336
$1.13 P/Share
|
|
Dec 12
2023
|
Matthew C Hill Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,500
+50.0%
|
$5,000
$2.19 P/Share
|
|
Nov 14
2023
|
Charles D. Goodwin Ii Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+35.71%
|
$50,000
$1.57 P/Share
|
|
Jul 12
2023
|
Lawrence Waldman Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
5,338
+50.0%
|
$10,676
$2.97 P/Share
|
|
Jun 26
2023
|
Todd Hornsby Executive Vice President |
SELL
Open market or private sale
|
Direct |
15,000
-99.73%
|
$105,000
$7.56 P/Share
|
|
Jun 26
2023
|
Todd Hornsby Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+50.0%
|
$15,000
$1.77 P/Share
|
|
Jun 06
2023
|
Michael Geraghty Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+26.67%
|
$20,000
$2.79 P/Share
|
|
Aug 29
2022
|
Charles D. Goodwin Ii Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
11,750
+12.9%
|
$58,750
$5.95 P/Share
|
|
Jul 11
2022
|
Moshe Citronowicz Sr. V.P. of Operations |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+6.17%
|
$60,000
$2.54 P/Share
|
|
Jul 11
2022
|
Lawrence Waldman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
24,000
+38.98%
|
$48,000
$2.54 P/Share
|
|
Jul 06
2022
|
Michael Geraghty Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+18.6%
|
$8,000
$2.54 P/Share
|
|
Jul 05
2022
|
Andrew Makrides Director |
SELL
Payment of exercise price or tax liability
|
Direct |
13,583
-2.13%
|
$81,498
$6.14 P/Share
|
|
Jul 05
2022
|
Andrew Makrides Director |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+4.49%
|
$60,000
$2.54 P/Share
|
|
May 19
2022
|
Lawrence Waldman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,000
+37.1%
|
$16,000
$2.79 P/Share
|
|
May 11
2022
|
Michael Geraghty Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+30.77%
|
$12,000
$2.79 P/Share
|
|
Mar 21
2022
|
Craig A. Swandal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
17,000
+50.0%
|
$68,000
$4.98 P/Share
|
|
Jan 07
2022
|
Craig A. Swandal Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,173
+10.65%
|
$64,557
$9.42 P/Share
|
|
Mar 08
2021
|
Lawrence Waldman Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,563
+50.0%
|
$11,126
$2.81 P/Share
|
|
Mar 05
2021
|
Michael Geraghty Director |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$15,000
$2.81 P/Share
|